BR112022005895A2 - Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 - Google Patents

Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2

Info

Publication number
BR112022005895A2
BR112022005895A2 BR112022005895A BR112022005895A BR112022005895A2 BR 112022005895 A2 BR112022005895 A2 BR 112022005895A2 BR 112022005895 A BR112022005895 A BR 112022005895A BR 112022005895 A BR112022005895 A BR 112022005895A BR 112022005895 A2 BR112022005895 A2 BR 112022005895A2
Authority
BR
Brazil
Prior art keywords
aldose
inhibitors
phosphomanomutase
redutase
deficiency
Prior art date
Application number
BR112022005895A
Other languages
English (en)
Inventor
Perfetti Riccardo
Shendelman Shoshana
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of BR112022005895A2 publication Critical patent/BR112022005895A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A presente invenção refere-se a métodos para tratar PMM2-CDG com o uso de inibidores de aldose redutase.
BR112022005895A 2019-10-08 2020-10-07 Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 BR112022005895A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912441P 2019-10-08 2019-10-08
PCT/US2020/054607 WO2021071965A1 (en) 2019-10-08 2020-10-07 Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency

Publications (1)

Publication Number Publication Date
BR112022005895A2 true BR112022005895A2 (pt) 2022-06-28

Family

ID=75437528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005895A BR112022005895A2 (pt) 2019-10-08 2020-10-07 Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2

Country Status (10)

Country Link
US (1) US20220226323A1 (pt)
EP (1) EP4041219A4 (pt)
JP (1) JP2022552831A (pt)
CN (1) CN114667139A (pt)
AU (1) AU2020363699A1 (pt)
BR (1) BR112022005895A2 (pt)
CA (1) CA3153108A1 (pt)
IL (1) IL291946A (pt)
MX (1) MX2022004270A (pt)
WO (1) WO2021071965A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001057A (es) 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
WO2024064147A1 (en) * 2022-09-20 2024-03-28 Mayo Foundation For Medical Education And Research Treating congenital disorders of glycosylation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
HRP20231563T1 (hr) * 2016-06-21 2024-03-15 The Trustees Of Columbia University In The City Of New York 4-okso-3,4-dihidrotino[3,4-d]piridazinski spojevi kao inhibitori aldosoreduktaze i načini njihove upotrebe
MX2020001057A (es) * 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
WO2020040831A1 (en) * 2018-08-20 2020-02-27 Perlara Pbc Methods for treating congenital disorders of glycosylation
BR112021019596A2 (pt) * 2019-04-01 2021-11-30 Applied Therapeutics Inc Inibidores de aldose redutase

Also Published As

Publication number Publication date
IL291946A (en) 2022-06-01
JP2022552831A (ja) 2022-12-20
MX2022004270A (es) 2022-05-03
CA3153108A1 (en) 2021-04-15
EP4041219A4 (en) 2023-11-01
WO2021071965A1 (en) 2021-04-15
US20220226323A1 (en) 2022-07-21
EP4041219A1 (en) 2022-08-17
CN114667139A (zh) 2022-06-24
AU2020363699A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112022004451A2 (pt) Antagonistas de hpk1 e usos dos mesmos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
BR112021016650A2 (pt) Indóis substituídos por n e outros heterociclos para o tratamento de distúrbios cerebrais
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
ECSP16067303A (es) Heteroarilos y usos de estos
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
BR112021024236A2 (pt) Proteínas multiespecíficas
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112017025263A2 (pt) método para o tratamento de doença neurológica
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EA202191086A1 (ru) Комбинированная терапия меланомы
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
BR112021022784A2 (pt) Composições e métodos para tratamento do câncer
BR112021017661A2 (pt) Uso de compostos 8,9-di-hidrocanabidiol
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
BR112023002575A2 (pt) Inibidores de sarm1
CO2022000270A2 (es) Inhibidores de enzimas
CO2022000266A2 (es) Inhibidores de enzimas